Motus Therapeutics was a Boston-based biotechnology company developing peptide therapeutics for gastrointestinal diseases. Its lead program was relamorelin, a ghrelin agonist for diabetic gastroparesis. Allergan acquired Motus Therapeutics for $200 million upfront in December 2016.